The general agreement for patients whose AP is the form of presentation of CML is to go on with the TKI indefinitely if they achieve a good response, as it is the case with this patient. Given the patient’s high risk because of his CML phase, TKI discontinuation is not recommended, and treatment should be given indefinitely. One possibility would be to reduce dasatinib dose to 100 mg daily, taking into account the sustained good molecular response.

ORIGINAL CASE:
20 year old male
diagnosed as CML in AP in January 2017
no comorbidities
Started on Dasatinib 140 mg /day
His RQ-PCR is 0 % since last 2 years
Is he a candidate for TRF ? If yes when ?

Dear Team,

20 year old male

diagnosed as CML in AP in January 2017

no comorbidities

Started on Dasatinib 140 mg /day

His RQ-PCR is 0 % since last 2 years

Is he a candidate for TRF ? If yes when ?

Regards

Dr.Saurabh Bhave
Tata Medical Center, Kolkata